Clearside Biomedical, Inc.
CLSDQUS売上高
$2M
百万USD
営業利益
$-29M
百万USD
純利益
$-34M
百万USD
ROE
88.4%
最新FY
EPS
$-0.47
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $0M | $-7M | - |
| FY2021 | Q2 | $1M | $-6M | - |
| FY2021 | Q3 | $3M | $-5M | - |
| FY2021 | FY | $30M | $0M | $0.01 |
| FY2022 | Q1 | $0M | $-8M | - |
| FY2022 | Q2 | $0M | $-8M | - |
| FY2022 | Q3 | $0M | $-8M | $-0.13 |
| FY2022 | FY | $1M | $-33M | $-0.55 |
| FY2023 | Q1 | $0M | $-9M | $-0.15 |
| FY2023 | Q2 | $1M | $-9M | $-0.15 |
| FY2023 | Q3 | $1M | $-9M | $-0.15 |
| FY2023 | FY | $8M | $-32M | $-0.53 |
| FY2024 | Q1 | $0M | $-12M | $-0.17 |
| FY2024 | Q2 | $0M | $-8M | $-0.10 |
| FY2024 | Q3 | $1M | $-8M | $-0.10 |
| FY2024 | FY | $2M | $-34M | $-0.47 |
| FY2025 | Q1 | $2M | $-8M | $-0.11 |
| FY2025 | Q2 | $0M | $-4M | $-0.06 |
| FY2025 | Q3 | $0M | $-6M | $-1.14 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $0M | $2M | $8M | $30M | $1M | $8M | $2M |
| 営業利益 | $-25M | $-58M | $-83M | $-30M | $-18M | $-1M | $-30M | $-25M | $-29M |
| 純利益 | $-26M | $-59M | $-83M | $-31M | $-18M | $0M | $-33M | $-32M | $-34M |
| 総資産 | $85M | $40M | $44M | $27M | $19M | $43M | $51M | $34M | $25M |
| 純資産 | - | - | - | - | - | - | - | - | - |
| 自己資本 | $72M | $21M | $24M | $11M | $9M | $38M | $11M | $-16M | $-39M |
| 営業CF | - | - | $-79M | $-27M | $-13M | $-11M | $-13M | $-18M | $-25M |
| EPS | - | - | - | - | - | $0.01 | $-0.55 | $-0.53 | $-0.47 |
| BPS | $2.83 | $0.67 | $0.66 | $0.25 | $0.15 | $0.63 | $0.17 | $-0.21 | $-0.50 |
| ROE | -36.1% | -275.4% | -350.6% | -275.8% | -207.8% | 1.0% | -310.6% | 204.2% | 88.4% |